

SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:99, SEQ ID NO:102, and SEQ ID NO:104; and

(b) an isolated protein of at least about 20 amino acids in length, wherein said protein has an at least 20 contiguous amino acid region identical in sequence to a 20 contiguous amino acid region selected from the group consisting of SEQ ID NO:92, SEQ ID NO:97, SEQ ID NO:100, and SEQ ID NO:105,

wherein said isolated protein of (a) or (b) elicits an immune response against a canine IL-13 protein or has IL-13 activity.

34. (New) The isolated protein of Claim 33, wherein said protein is selected from the group consisting of:

(a) a protein having an amino acid sequence selected from the group consisting of SEQ ID NO:92, SEQ ID NO:97, SEQ ID NO:100, and SEQ ID NO:105; and  
(b) a protein encoded by an allelic variant of a nucleic acid molecule encoding a protein having an amino acid sequence selected from the group consisting of SEQ ID NO:92, SEQ ID NO:97, SEQ ID NO:100, and SEQ ID NO:105.

35. (New) The isolated protein of Claim 34, wherein the protein has the amino acid sequence of SEQ ID NO:92.

36. (New) The isolated protein of Claim 34, wherein the protein has the amino acid sequence of SEQ ID NO:97.

37. (New) The isolated protein of Claim 34, wherein the protein has the amino acid sequence of SEQ ID NO:100.

38. (New) The isolated protein of Claim 34, wherein the protein has the amino acid sequence of SEQ ID NO:105.

*Sub 82*  
39. (New) An isolated protein having an amino acid sequence that is at least about 70 percent identical to an amino acid sequence selected from the group consisting of SEQ ID NO:92, SEQ ID NO:97, SEQ ID NO:100, and SEQ ID NO:105, wherein said protein elicits an immune response against a canine IL-13 protein or has IL-13 activity.

*A' conc*  
40. (New) A therapeutic composition comprising a therapeutic compound selected from the group consisting of:

- (a) the isolated protein of Claim 33;
- (b) a mimotope of said protein of (a);
- (c) a multimeric form of said protein of (a);
- (d) an antibody that selectively binds to said protein of (a); and
- (e) an inhibitor of a immunoregulatory protein activity identified by its ability to inhibit the activity of said protein of (a).

*9.*  
~~41~~ (New) The composition of Claim ~~40~~<sup>8</sup>, wherein said composition further comprises a component selected from the group consisting of an excipient, an adjuvant and a carrier.

*42 10* (New) A method to regulate an immune response in an animal comprising administering to the animal the therapeutic composition of Claim ~~40~~<sup>8</sup>.

*Sub 83*  
43. (New) The method of Claim 42, wherein said animal is selected from the group consisting of canids.

*12.*  
~~44~~ (New) The method of Claim ~~42~~<sup>10</sup>, wherein said composition further comprises a component selected from the group consisting of an excipient, an adjuvant and a carrier.